

REMARKS

The specification has been amended to reflect the 371 status.

The claims have been amended to better conform to U.S. practice. Specifically, claims 1, 22 and 23 have been amended to remove the brackets. Claim 7 has been amended to recite a second component of the pharmaceutical composition, a pharmaceutically acceptable additive. Support is found in the specification at page 29, lines 8-12. Claim 12 has been amended to remove the multiple dependency to reduce the PTO filing fee. Claims 19-21 have been rewritten in U.S. format.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "Version with markings to show changes made".

Favorable action on the merits is solicited.

Respectfully submitted,

Keiji KAMIYAMA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 13, 2001